Dolutegravir vs Elvitegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by GlaxoSmithKline and partners
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)
Result source: NCT01263015
Elvitegravir · Stribild
Marketed by Gilead Sciences and partners
NCT01095796 · Phase 3 · completed
Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.
Reported efficacy
The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)
Result source: NCT01095796
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dolutegravir | Elvitegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 88% vs 85%vs RTGNCT0122782412 other results
| 87.6% vs 84.1%vs AtriplaNCT0109579634 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT01837277 | —Not reported |
| CD4 count, change (week 48) | 163 vs 174−11 vs placeboNCT0156889244 other results
| 321 vs 300vs AtriplaNCT0109579626 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Dolutegravir
- 88% vs 85%vs RTGNCT01227824
12 other results
- 90% vs 83% NCT01449929
- 88% vs 81% NCT01263015
- 90% vs 93% NCT02831673
- 93% vs 94% NCT02831764
- 71% vs 63% NCT01263015
- 77% vs 70% NCT01263015
- 79% vs 83% NCT02831673
- 84% vs 84% NCT02831764
- 84% vs 89% NCT02831673
- 88% vs 90% NCT02831764
- 92% vs 93% NCT02831673
- 94% vs 94% NCT02831764
- Elvitegravir
- 87.6% vs 84.1%vs AtriplaNCT01095796
34 other results
- 91.6% vs 88.5% NCT01797445
- 87.2% vs 80.8% NCT01705574
- 93.1% vs 92.8% NCT01780506
- 59% vs 57.8% NCT00708162
- 93.8% vs 87.1% NCT01475838
- 93.4% vs 88.1% NCT01495702
- 89.5% vs 86.8% NCT01106586
- 80.2% vs 75.3% NCT01095796
- 86.9% vs 83.1% NCT01780506
- 77.6% vs 74.6% NCT01106586
- 84.2% vs 81.5% NCT01095796
- 92.8% vs 89.1% NCT01815736
- 84% vs 82.3% NCT01797445
- 89.2% vs 88.2% NCT01780506
- 47.6% vs 45% NCT00708162
- 52.4% vs 53% NCT00708162
- 53.6% vs 56.4% NCT00708162
- 86.9% vs 69.8% NCT01475838
- 86.6% vs 80.4% NCT01495702
- 83.3% vs 82.3% NCT01106586
- 85.9% vs 83.2% NCT01095796
- 88.8% vs 85.5% NCT01095796
- 59.8% vs 57.5% NCT00708162
- 61% vs 60.7% NCT00708162
- 86.1% vs 84.8% NCT01106586
- 91.5% vs 88.5% NCT01106586
- 76.1% vs 78.1% NCT01095796
- 78.4% vs 73.1% NCT01106586
- 88.4% vs 89.7% NCT01497899
- 89.6% vs 87% NCT00869557
- 88.4% vs 87.9% NCT01497899
- 89.6% vs 87% NCT00869557
- 91.7% vs 82.6% NCT00869557
- 89.6% vs 87% NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)
- Dolutegravir
- —Not posted · NCT01837277
- Elvitegravir
- —Not reported
CD4 count, change (week 48)
- Dolutegravir
- 163 vs 174−11 vs placeboNCT01568892
44 other results
- 170 vs 146 NCT01568892
- 115 vs 156 NCT01568892
- 90.5 vs 125.5 NCT01568892
- 48 vs 135.5 NCT01568892
- 39 vs 117 NCT01568892
- 292.2 vs 286.2 NCT01227824
- 281.3 vs 292.9 NCT01227824
- 247.8 vs 278.6 NCT01227824
- 247.8 vs 264.2 NCT01227824
- 238.9 vs 257.5 NCT01227824
- 248.8 vs 230.7 NCT01910402
- 224.1 vs 239.8 NCT01227824
- 230.7 vs 191.4 NCT01910402
- 223.4 vs 241.3 NCT01227824
- 199.3 vs 204.2 NCT01227824
- 200.6 vs 163 NCT01910402
- 378.5 vs 331.6 NCT01263015
- 379.5 vs 333.3 NCT01263015
- 377.9 vs 327.2 NCT01263015
- 347 vs 311 NCT01263015
- 349.3 vs 298.9 NCT01263015
- 322.6 vs 286 NCT01263015
- 315.2 vs 272.1 NCT01263015
- 306.1 vs 269.6 NCT01263015
- 271.3 vs 235.3 NCT01263015
- 267.5 vs 209.5 NCT01263015
- 265.5 vs 216.2 NCT01263015
- 250.5 vs 208.1 NCT01263015
- 216.9 vs 177.8 NCT01263015
- 301.8 vs 303.2 NCT02831673
- 301.7 vs 296.6 NCT02831764
- 264.7 vs 253.8 NCT02831673
- 272 vs 264.6 NCT02831764
- 265 vs 230 NCT02259127
- 311 vs 230 NCT02259127
- 228 vs 230 NCT02259127
- 222.2 vs 217.7 NCT02831673
- 225.7 vs 217.2 NCT02831764
- 192.2 vs 175.1 NCT02831673
- 188.8 vs 163.2 NCT02831764
- 72 vs 230 NCT02259127
- 39 vs 28 NCT02263326
- 88 vs 75 NCT03991013
- 111 vs 101 NCT03851588
- Elvitegravir
- 321 vs 300vs AtriplaNCT01095796
26 other results
- 323 vs 310 NCT01780506
- 280 vs 293 NCT01106586
- 295 vs 273 NCT01095796
- 360 vs 328 NCT01095796
- 60 vs 42 NCT01815736
- 274 vs 260 NCT01797445
- 285 vs 271 NCT01780506
- 205 vs 198 NCT00708162
- 61 vs 71 NCT01475838
- 83 vs 101 NCT01495702
- 256 vs 261 NCT01106586
- 338 vs 340 NCT01106586
- 239 vs 206 NCT01095796
- 225 vs 200 NCT01797445
- 221 vs 212 NCT01705574
- 235 vs 221 NCT01780506
- 207 vs 211 NCT01106586
- 56 vs -1 NCT02616783
- 138 vs 147 NCT00708162
- 40 vs 32 NCT01475838
- 56 vs 58 NCT01495702
- 48 vs -4 NCT02616783
- 177 vs 204 NCT01497899
- 240 vs 166 NCT00869557
- 165 vs 179 NCT01497899
- 161 vs 117 NCT00869557
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Dolutegravir: 10 of 10 rows · Elvitegravir: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dolutegravir Rows use multiple source trials | Elvitegravir Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 110 cells/uL @ 48wk50 mg BIDa,b,c NCT01328041 · Phase 3 | 229 cells/uL @ 48wka,b,c NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Maintenance | -2.99 vs -3.06 EFV/TDF/FTC log @ 96wk50 mg plus 600/300 mg once dailyd NCT01263015 · Phase 3 · combination · HIV · phase 3 1 other source trial-2.938 vs -2.901 RTG log @ 96wk50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 | -2.26 vs -2.31 Raltegravir log @ 96wkd NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.321 log @ 48wk50 mg BIDa,b,c NCT01328041 · Phase 3 | -3.16 log @ 48wka,b,c NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 400 Copies responder rate · % of participants Maintenance | 92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once dailyb,c NCT01449929 · Phase 3 | 68.1% (n=351) vs 67.2% (n=351) Raltegravir @ 48wke,b,c NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 show 1 more dose70.1% (n=351) vs 72.1% (n=351) Raltegravir @ 48wk NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 |
| HIV-1 RNA Less Than 50 event count · % of participants No placebo or comparator arm | 68.9% (n=183) @ 24wk*50 mg BIDf,b,c NCT01328041 · Phase 3 · converted to % from 126 participants as posted | 95.2% (n=21) @ 24wk*f,b,c NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted |
| HIV-1 RNA LT 50 Copies responder rate · % of participants No placebo or comparator arm | 100% (n=149) @ 432wkb,c NCT01910402 · Phase 3 · registry result, not featured evidence | 94.6% (n=223)e,b,c NCT02397096 · Phase 3 · registry result, not featured evidence show 3 more doses94.6% (n=223) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence 90.8% (n=447) NCT02397096 · Phase 3 · registry result, not featured evidence 93.7% (n=447) @ 24wk NCT02397096 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 17.4%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results26%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 13.6%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 31.1%50 mg BID NCT01328041 · Phase 3 8.5% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 10.7% NCT04585737 · Phase 4 · registry result, not featured evidence 25.6%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 13.1%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 16.2%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 11.4%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 7.8%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 4.7%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence 0%50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 0%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 0%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 23.9% NCT01837277 · Phase 2/3 · registry result, not featured evidence 0%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 1.5% NCT03991013 · Phase 2 · registry result, not featured evidence 3.8% NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 83.6%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results22.2% NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 6.3%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 20%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 16%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 43.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.9%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 80.7% NCT01106586 · Phase 3 · registry result, not featured evidence 0% NCT01533259 · Phase 3 · registry result, not featured evidence 14% NCT01721109 · Phase 2/3 · registry result, not featured evidence 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 6.3% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results2.9%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 2.1%50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 —50 mg once daily NCT01449929 · Phase 3 3.8%50 mg BID NCT01328041 · Phase 3 — NCT04880395 · Phase 4 · registry result, not featured evidence · combination — NCT04585737 · Phase 4 · registry result, not featured evidence —Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination —Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence —DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence —DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 2.8%DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination —Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination —Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination — NCT02263326 · Phase 3 · registry result, not featured evidence · combination 7.7%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence —Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence —Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence — NCT01837277 · Phase 2/3 · registry result, not featured evidence —50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence —50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence — NCT03991013 · Phase 2 · registry result, not featured evidence — NCT03851588 · Phase 2 · registry result, not featured evidence —Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence —Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence —Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 2.5%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results— NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 0.4%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 1.6%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0.9%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 0.7%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 2.5% NCT01106586 · Phase 3 · registry result, not featured evidence — NCT01533259 · Phase 3 · registry result, not featured evidence — NCT01721109 · Phase 2/3 · registry result, not featured evidence 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence — NCT00869557 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.7%50 mg plus 600/300 mg once dailyg NCT01263015 · Phase 3 · combination · HIV · phase 3 show 41 more results10%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 6.2%50 mg Once a Day NCT01227824 · Phase 3 · HIV · phase 3 —50 mg once daily NCT01449929 · Phase 3 14.9%50 mg once daily NCT01449929 · Phase 3 3.3%50 mg once daily NCT01449929 · Phase 3 25.1%50 mg BID NCT01328041 · Phase 3 9.9% NCT04880395 · Phase 4 · registry result, not featured evidence · combination 8.1% NCT04585737 · Phase 4 · registry result, not featured evidence 7.7%Abacavir/Dolutegravir/Lamivudine(A NCT03016533 · Phase 3 · registry result, not featured evidence · combination 8.2%Dolutegravir (DTG) NCT03016533 · Phase 3 · registry result, not featured evidence 8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD NCT01910402 · Phase 3 · registry result, not featured evidence 2.1%DTG + 3TC-Continuation Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC-Double Blind Phase NCT02831673 · Phase 3 · registry result, not featured evidence · combination 10.4%DTG + 3TC-Double-blind Phase + Ope NCT02831673 · Phase 3 · registry result, not featured evidence · combination 3.6%DTG + 3TC - Continuation Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination —DTG + 3TC - Double-blind Phase NCT02831764 · Phase 3 · registry result, not featured evidence · combination 10.8%DTG + 3TC - Double-blind Phase + O NCT02831764 · Phase 3 · registry result, not featured evidence · combination 18%Arm 1: Maternal DTG+FTC/TAF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 18.1%Arm 2: Maternal DTG+FTC/TDF NCT03048422 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 15.4%50 mg OD NCT01499199 · Phase 3 · registry result, not featured evidence —50 mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 35.7%50mg BID NCT01568892 · Phase 3 · registry result, not featured evidence 26.2%Dolutegravir (<14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 10%Dolutegravir (>=14kg Cohort) NCT02259127 · Phase 2/3 · registry result, not featured evidence 14.9%Dolutegravir - ODYSSEY A (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 6.1%Dolutegravir - ODYSSEY B (>=14kg C NCT02259127 · Phase 2/3 · registry result, not featured evidence 9.8% NCT01837277 · Phase 2/3 · registry result, not featured evidence 6.9%50 mg od NCT02245022 · Phase 2/3 · registry result, not featured evidence 6.7%50 mg BID NCT05630872 · Phase 2 · registry result, not featured evidence 3.1% NCT03991013 · Phase 2 · registry result, not featured evidence 0% NCT03851588 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Stratum 1A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 1 Stratum 1C NCT05406583 · Phase 1 · registry result, not featured evidence 7.1%Cohort 2 Stratum 2A NCT05406583 · Phase 1 · registry result, not featured evidence 0%Cohort 2 Stratum 2B NCT05406583 · Phase 1 · registry result, not featured evidence 0%Arm 1 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%Arm 2 Dolutegravir NCT04771754 · Phase 1 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence | 19.8%h NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results0% NCT02477527 · Phase 4 · registry result, not featured evidence 1.9%DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 6.4%DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.5%DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 2.3%DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence 2.9%ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence 2.6%ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 9.3%ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.3%ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 3.6%ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 16.8%Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 20.6% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 8.2% NCT01475838 · Phase 3 · registry result, not featured evidence 8.9%All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.2%Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 16.4% NCT01106586 · Phase 3 · registry result, not featured evidence 2.1% NCT01533259 · Phase 3 · registry result, not featured evidence 10% NCT01721109 · Phase 2/3 · registry result, not featured evidence 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.2% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mg plus 600/300 mg once dailyg diarrhoea 22.7% nasopharyngitis 20.8% insomnia 17.9% NCT01263015 · Phase 3 · combination · HIV · phase 3 show 31 more results50 mg Once a Day upper respiratory tract infection 8% syphilis 7.1% viral upper respiratory tract infection 7.1% NCT01227824 · Phase 3 · HIV · phase 3 50 mg once daily viral upper respiratory tract infection 4.1% gastroenteritis 2.4% asthenia 1.6% NCT01449929 · Phase 3 insomnia/nightmares 3.9% alopecia 2% itching/rash/prurigo 2% NCT04880395 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 8.7% headache 8.1% urinary tract infection 6% NCT01910402 · Phase 3 · registry result, not featured evidence nausea 18.5% headache 11.7% diarrhoea 9.3% NCT01910402 · Phase 3 · registry result, not featured evidence covid-19 6.9% suspected covid-19 3.4% headache 3% NCT02831673 · Phase 3 · registry result, not featured evidence · combination headache 14.3% diarrhoea 14% nasopharyngitis 13.8% NCT02831673 · Phase 3 · registry result, not featured evidence · combination covid-19 6% syphilis 4% respiratory tract infection viral 3.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.6% upper respiratory tract infection 13.1% nasopharyngitis 12.2% NCT02831764 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 83.9% blood creatinine increased 78.3% haemoglobin decreased 3.7% NCT03048422 · Phase 3 · registry result, not featured evidence · combination creatinine renal clearance decreased 89.8% blood creatinine increased 83.3% haemoglobin decreased 9.3% NCT03048422 · Phase 3 · registry result, not featured evidence · combination grade 3 bilirubinemia 0% NCT02263326 · Phase 3 · registry result, not featured evidence · combination 50 mg OD headache 53.8% upper respiratory tract infection 38.5% diarrhoea 30.8% NCT01499199 · Phase 3 · registry result, not featured evidence 50mg BID diarrhoea 21.4% (placebo 12.5%) headache 21.4% (placebo 6.3%) lymphadenopathy 21.4% (placebo 0%) NCT01568892 · Phase 3 · registry result, not featured evidence cns disturbances 0% NCT01837277 · Phase 2/3 · registry result, not featured evidence 50 mg BID abnormal loss of weight 10% blood pressure increased 10% headache 10% NCT05630872 · Phase 2 · registry result, not featured evidence acute psychosis 1.5% (placebo 0%) incident pulmonary tuberculosis 1.5% (placebo 0%) acute kidney injury 0% (placebo 3.1%) NCT03991013 · Phase 2 · registry result, not featured evidence insomnia 5.7% (placebo 0%) NCT03851588 · Phase 2 · registry result, not featured evidence haemoglobin decreased 33.3% alanine aminotransferase increased 16.7% aspartate aminotransferase increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 50% alanine aminotransferase increased 16.7% blood bilirubin increased 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 83.3% neutrophil count decreased 50% acne infantile 16.7% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 42.9% blood bilirubin increased 35.7% dermatitis diaper 21.4% NCT05406583 · Phase 1 · registry result, not featured evidence haemoglobin decreased 56.3% neutrophil count decreased 31.3% blood bilirubin increased 25% NCT05406583 · Phase 1 · registry result, not featured evidence hypokalaemia 71.4% (placebo 71.4%) hypoglycaemia 42.9% (placebo 71.4%) vivid dreams 28.6% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence hypokalaemia 62.5% (placebo 71.4%) cold 25% (placebo 14.3%) bloating 12.5% (placebo 0%) NCT04771754 · Phase 1 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence | h diarrhoea 26.7% upper respiratory tract infection 26.4% nausea 23% NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 31 more resultsheadache 6.7% diarrhoea 4.3% nasopharyngitis 4.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.4% headache 6.4% diarrhoea 5.4% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 3.9% headache 1.9% back pain 1.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% headache 6.5% diarrhoea 4.5% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.4% back pain 3.7% diarrhoea 3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.8% headache 5.5% arthralgia 5.3% NCT02397096 · Phase 3 · registry result, not featured evidence back pain 2.3% arthralgia 1.7% nasopharyngitis 1.7% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 8.3% arthralgia 1.2% diarrhoea 1.2% NCT02397096 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.4% nasopharyngitis 5.2% diarrhoea 4.4% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% diarrhoea 5.2% nasopharyngitis 4.7% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.5% diarrhoea 11.4% nasopharyngitis 10% NCT01815736 · Phase 3 · registry result, not featured evidence diarrhoea 23% headache 22.7% upper respiratory tract infection 20.2% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 3.5% headache 2.8% arthralgia 1.4% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% cough 2.5% syphilis 2.5% NCT01797445 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence diarrhoea 25.7% upper respiratory tract infection 21.1% nausea 16.8% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 cough 4.4% syphilis 4.4% upper respiratory tract infection 3.3% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 33.9% upper respiratory tract infection 21.2% headache 13.8% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.3% upper respiratory tract infection 9.9% diarrhoea 9.2% NCT01475838 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.2% nasopharyngitis 10.2% NCT01495702 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.3% nasopharyngitis 10.3% NCT01495702 · Phase 3 · registry result, not featured evidence diarrhoea 28% upper respiratory tract infection 24.4% nausea 22.7% NCT01106586 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.8% insomnia 12.5% anxiety 10.4% NCT01533259 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 36% headache 24% vomiting 20% NCT01721109 · Phase 2/3 · registry result, not featured evidence nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 27.1% fatigue 16.7% headache 14.6% NCT00869557 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2/3 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation context differs: prior_therapy differs (experienced versus naive).
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 4 versus Phase 3.
- gPopulation comparability has not been reviewed for 39 of these studies.
- hPopulation comparability has not been reviewed for 34 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dolutegravir
show 3 more results
show 3 more results
show 1 more result
+ 73 further endpoints in the CSV export.
Elvitegravir
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 5 more results
show 11 more results
show 1 more result
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dolutegravir's landscape · Elvitegravir's landscape